RN Mobile Menu

Search form


Rheumatology Network

Cold fingers? Is it primary or secondary Raynaud’s?

Raynaud’s phenomenon affects up to 5% of the general population, but for 37% of patients, it leads to connective tissue disease. In this slideshow, we compare primary and secondary Raynaud’s.  (Raynaud’s phenomenon, ©Twinschoice/Shutterstock.com)

Recent Content


Patients with moderate-to-severe psoriasis who switch biologic medications at the end of a clinical trial should go through an induction period.


Once daily baricitinib for rheumatoid arthritis leads to significant clinical improvements for patients who failed conventional synthetic DMARDs, a new study shows.


Biologic anti-inflammatory agents can lead to a drop in coronary artery disease in psoriasis patients, a study shows.

Pyoderma gangrenosum (©UBMMedicaLLC). Photo by Irina Litvin, D.O

Photo Clinic: A case of pyoderma gangrenosum that failed antibiotics, steroids, other immunosuppressive agents, thalidomide and cyclosporine.

Pyoderma gangrenosum (©UBMMedicaLLC). Photo by Irina Litvin, D.O.

Case Study: A female patient presents with a case of pyoderma gangrenosum that fails multiple standard treatments.


In this slideshow, we highlight some of the upcoming studies due to be presented at the American College of Rheumatology 2016 annual meeting which begins Nov. 11 in Washington, D.C.


PsA patients show sustained improvement at two years with secukinumab, clinical trial shows.

By clicking Accept, you agree to become a member of the UBM Medica Community.